A Study to Evaluate Sapablursen (Formerly ISIS 702843, IONIS-TMPRSS6-LRx) in Patients With Polycythemia Vera
← catalyst calendarSponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →.
Phase
Phase 2
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
50actual
Sites
13
Countries
Australia, Canada, Poland +2
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-12-30 | actual | When the study began enrolling |
| Primary completion | 2025-06-26 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-02 | actual | The whole study's end, after follow-up |
| First posted | 2021-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Phlebotomy Dependent Polycythemia Vera
Intervention
- Drug: sapablursen — also filed as ISIS 702843, IONIS-TMPRSS6-LRx
Primary outcome
what the primary-completion date above is the date OFChange in the frequency of phlebotomy comparing Baseline with the last 20 weeks of the 37 week Treatment Period
measured Week 17 to Week 37
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed